LYNNTECH INC. — Department of Health and Human Services SBIR Phase I: NCEZID

Description

PROJECT SUMMARY Invasive candidiasis is a serious and widely recognized fungal infection caused by Candida speciesAntifungal resistance is a particular problem with Candida infectionsMultidrug resistant Candida infections have very few remaining treatment optionsThe type and level of drug resistance is unknown until the causative Candida species is determined via culture methodsA rapid diagnostic test to both identify Candida species and its antifungal drug resistance would help provide timelyappropriate treatment and reduce the spread of these resistant organismsIn response to a research topic that is specified by CDC for a culture independent platform technology for Candida diagnosis and resistance identification for point of carelow resource settingsLynntech proposes to develop a rapidinexpensivespecificand sensitive diagnostic that enables point of care Candida species and multidrug resistance identification without the need to rely on culture resultsThe innovation of our diagnostic test is effectively bringing highly sensitive molecular testing to point of careLynntech s diagnostic test could potentially represent a significant new paradigm in point of care diagnosis to guide accurate therapy for Candida infections and help maximize positive patient outcomes PROJECT NARRATIVE Invasive candidiasis is a serious fungal infection caused by Candida species that usually confer resistance to antifungal drugsA rapid diagnostic test to both identify Candida species and detect antifungal drug resistance would help provide timelyappropriate treatment and reduce the spread of these resistant organismsLynntech proposes to develop an inexpensivespecificsensitivepoint of care amenableuser friendly and rapid diagnostic for Candida species and multidrug resistance identification to enable effectivenon empirical therapeutic prescription without the need to rely on culture results